Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian DME Patients in a Real-World Setting: The PRECISE Study

Related

• 

  Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study

  Eric W Schneider, MD

  Updates from the Field

  2025

• 

  48-Week End of Study Results From BEHOLD Phase 2 Study of UBX1325 in Patients With DME

  Arshad M. Khanani, MD, MA, FASRS

  Annual Meeting Talks

  2023

• 

  Expert Panel: Pegcetacoplan Safety

  Andre J. Witkin, MD

  David A. Eichenbaum, MD, FASRS

  Samuel Anthony Minaker, MD, MSc

  Janani Singaravelu, MS, MD

  Sunir J. Garg, MD, FACS, FASRS

  Annual Meeting Talks

  2024